Biotech | August 02, 2021
Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company has already embarked upon significant expansion in Turkey
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
Subscribe To Our Newsletter & Stay Updated
